Highlights Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
21.55 ^HKD	-0.92%		+8.40%	+5.38%

Apr. 26	Central Bank, Tech Outlooks Lift Major Asian Stock Markets	MT
Apr. 16	Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Central Bank, Tech Outlooks Lift Major Asian Stock Markets	Apr. 26	MT
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	Apr. 16	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27	MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue	Mar. 24	MT
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024	Mar. 24	CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 24	CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings	Mar. 21	MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%	Mar. 21	MT
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer	Feb. 22	MT
Sinopharm offers to take China-TCM private in nearly $3 bln deal	Feb. 21	RE
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	Feb. 20	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	Feb. 20	MT
Sinopharm to Renew Financial Services Deal with Affiliate	Dec. 28	MT
Hutchmed China renews deals with "substantial" shareholders	Dec. 21	AN
Linklogis to Offload Entire 19.6% Stake in Pharma Supply Chain Financing Associate	Nov. 23	MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	Nov. 07	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Sinopharm's Nine-Month Attributable Profit Rises on Higher Revenue; Shares Fall 3%	23-10-29	MT
China National Accord Medicines' Profit Slides 4% in Q3	23-10-26	MT
China National Medicines' Profit Drops 16.1% in Q3	23-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Highlights

Filters